Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk

Methods in Molecular Biology

Volumn 471, Issue , 2009, Pages 361-385

  Park, Jong Y ^a   Huang, Yifan ^a   Sellers, Thomas A ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer susceptibility; DNA repair; Environmental exposure; Polymorphism; Prostate cancer

Indexed keywords

DNA REPAIR; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; PROSTATE TUMOR; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

DNA REPAIR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 60349120505     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-59745-416-2_18     Document Type: Review

References (106)

1. American Cancer Society. (2007). Cancer Facts & Figures 2007. American Cancer Society, Atlanta, GA.
2. Hsing, A.W., L. Tsao, and S.S. Devesa. (2000). International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85, 60-7.
3. Crawford, E.D. (2003) Epidemiology of prostate cancer. Urology 62, 3-12.
4. Noble, R.L. (1977). The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 37, 1929-33.
5. Henderson, B.E., R.K. Ross, M.C. Pike, and J.T. Casagrande (1982). Endogenous hormones as a major factor in human cancer. Cancer Res 42, 3232-9.
6. Friedberg, E.C. (2001). How nucleotide excision repair protects against cancer. Nat Rev Cancer 1, 22-33.
7. Mullaart, E., P.H. Lohman, F. Berends, and J. Vijg. (1990). DNA damage metabolism and aging. Mutat Res 237, 189-210.
8. Wood, R.D., M. Mitchell, J. Sgouros, and T. Lindahl. (2001). Human DNA repair genes. Science 291, 1284-9.
9. Goode, E.L., C.M. Ulrich, and J.D. Potter. (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 11, 1513-30.
10. Hirata, H., Y. Hinoda, Y. Tanaka, N. Okayama, Y. Suehiro, K. Kawamoto, N. Kikuno, S. Majid, K. Vejdani, and R. Dahiya. (2007). Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 43, 231-7.
11. Chen, L., C.B. Ambrosone, J. Lee, T.A. Sellers, J. Pow-Sang, and J.Y. Park. (2006). Association between polymorphisms in the DNA repair genes XRCC1 and APE1, and the risk of prostate cancer in white and black Americans. J Urol. 175, 108-12; discussion 112.
12. Ritchey, J.D., W.Y. Huang, A.P. Chokkalingam, Y.T. Gao, J. Deng, P. Levine, F.Z. Stanczyk, and A.W. Hsing. (2005). Genetic variants of DNA repair genes and prostate cancer: a population-based study. Cancer Epidemiol Biomarkers Prev 14, 1703-9.
13. Rybicki, B.A., D.V. Conti, A. Moreira, M. Cicek, G. Casey, and J.S. Witte. (2004). DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 13, 23-9.
14. Chen, L., A. Elahi, J. Pow-Sang, P. Lazarus, and J. Park. (2003). Association between polymorphism of human oxoguanine glyco sylase 1 and risk of prostate cancer. J Urol. 170, 2471-4.
15. van Gils, C.H., R.M. Bostick, M.C. Stern, and J.A. Taylor. (2002). Differences in base excision repair capacity may modulate the effect of dietary antioxidant intake on prostate cancer risk: an example of polymorphisms in the XRCC1 gene. Cancer Epidemiol Biomarkers Prev 11, 1279-84.
16. Xu, J., S.L. Zheng, A. Turner, S.D. Isaacs, K.E. Wiley, G.A. Hawkins, B.L. Chang, E.R. Bleecker, P.C. Walsh, D.A. Meyers, and W.B. Isaacs. (2002). Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 62, 2253-7.
17. Lockett, K.L., I.V. Snowhite, and J.J. Hu. (2005). Nucleotide-excision repair and prostate cancer risk. Cancer Lett 220, 125-35.
18. Nock, N.L., M.S. Cicek, L. Li, X. Liu, B.A. Rybicki, A. Moreira, S.J. Plummer, G. Casey, and J.S. Witte. (2006). Polymorphisms in estrogen bioactivation, detoxification and oxidative DNA base excision repair genes and prostate cancer risk. Carcinogenesis. 27, 1842-8.
19. Xu, Z., L.X. Qian, L.X. Hua, X.R. Wang, J. Yang, W. Zhang, and H.F. Wu. (2007). Relationship between DNA repair gene XRCC1 Arg399Gln polymorphism and susceptibility to prostate cancer in the Han population in Jiangsu and Anhui. Zhonghua Nan Ke Xue 13, 327-31.
20. Liu, Z., L.E. Wang, S.S. Strom, M.R. Spitz, R.J. Babaian, J. DiGiovanni, and Q. Wei. (2003). Overexpression of hMTH in peripheral lymphocytes and risk of prostate cancer: a case-control analysis. Mol Carcinog 36, 123-9.
21. Strom, S.S., M.R. Spitz, Y. Yamamura, R.J. Babaian, P.T. Scardino, and Q. Wei (2001). Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study. Prostate 47, 269-75.
22. Chen, Y., J. Wang, M.M. Fraig, K. Henderson, N.K. Bissada, D.K. Watson, and C.W. Schweinfest. (2003). Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer. Int J Oncol 22, 1033-43.
23. Chen, Y., J. Wang, M.M. Fraig, J. Metcalf, W.R. Turner, N.K. Bissada, D.K. Watson, and C.W. Schweinfest. (2001). Defects of DNA mismatch repair in human prostate cancer. Cancer Res 61, 4112-21.
24. Hu, J.J., M.C. Hall, L. Grossman, M. Hedayati, D.L. McCullough, K. Lohman, and L.D. Case. (2004). Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res 64, 1197-201.
25. Nam, R.K., W.W. Zhang, M.A. Jewett, J. Trachtenberg, L.H. Klotz, M. Emami, L. Sugar, J. Sweet, A. Toi, and S.A. Narod. (2005). The use of genetic markers to determine risk for prostate cancer at prostate biopsy. Clin Cancer Res 11, 8391-7.
26. Goodman, M., R.M. Bostick, K.C. Ward, P.D. Terry, C.H. van Gils, J.A. Taylor, and J.S. Mandel. (2006). Lycopene intake and prostate cancer risk: effect modification by plasma antioxidants and the XRCC1 genotype. Nutr Cancer 55, 13-20.
27. Lockett, K.L., M.C. Hall, J. Xu, S.L. Zheng, M. Berwick, S.C. Chuang, P.E. Clark, S.D. Cramer, K. Lohman, and J.J. Hu. (2004). The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64, 6344-8.
28. Hebbring, S.J., H. Fredriksson, K.A. White, C. Maier, C. Ewing, S.K. McDonnell, S.J. Jacobsen, J. Cerhan, D.J. Schaid, T. Ikonen, V. Autio, T.L. Tammela, K. Herkommer, T. Paiss, W. Vogel, M. Gielzak, J. Sauvageot, J. Schleutker, K.A. Cooney, W. Isaacs, and S.N. Thibodeau. (2006). Role of the nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 15, 935-8.
29. Angele, S., A. Falconer, S.M. Edwards, T. Dork, M. Bremer, N. Moullan, B. Chapot, K. Muir, R. Houlston, A.R. Norman, S. Bullock, Q. Hope, J. Meitz, D. Dearnaley, A. Dowe, C. Southgate, A. Ardern-Jones, D.F. Easton, R.A. Eeles, and J. Hall. (2004). ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 91, 783-7.
30. Xu, Z., L.X. Hua, L.X. Qian, J. Yang, X.R. Wang, W. Zhang, and H.F. Wu. (2007). Relationship between XRCC1 polymorphisms and susceptibility to prostate cancer in men from Han, Southern China. Asian J Androl 9, 331-8.
31. Demple, B. and L. Harrison. (1994). Repair of oxidative damage to DNA: enzymology and biology. Annu Rev Biochem 63, 915-48.
32. Robson, C.N., and I.D. Hickson. (1991). Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res 19, 5519-23.
33. Wilson, D.M., 3rd, and D. Barsky. (2001). The major human abasic endonuclease: formation, consequences and repair of abasic lesions in DNA. Mutat Res 485, 283-307.
34. Boiteux, S. and J.P. Radicella. (2000). The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys 377, 1-8.
35. Sunaga, N., T. Kohno, K. Shinmura, T. Saitoh, T. Matsuda, R. Saito, and J. Yokota. (2001). OGG1 protein suppresses G:C - >T: A mutation in a shuttle vector containing 8-hydroxyguanine in human cells. Carcinogenesis 22, 1355-62.
36. Lindahl, T., and R.D. Wood. (1999). Quality control by DNA repair. Science. 286, 1897-905.
37. Kohno, T., K. Shinmura, M. Tosaka, M. Tani, S.R. Kim, H. Sugimura, T. Nohmi, H. Kasai, and J. Yokota. (1998). Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNA. Oncogene 16, 3219-25.
38. National Center for Biotechnology Information (2006). SNP500 Cancer. Cancer Genome Anatomy Project. Cited in http://snp500cancer.nci.nih.gov.
39. Shinmura, K., T. Kohno, H. Kasai, K. Koda, H. Sugimura, and J. Yokota. (1998). Infrequent mutations of the hOGG1 gene, that is involved in the excision of 8-hydroxyguanine in damaged DNA, in human gastric cancer. Jpn. J. Cancer Res. 89, 825-8.
40. Janssen, K., K. Schlink, W. Gotte, B. Hippler, B. Kaina, and F. Oesch. (2001). DNA repair activity of 8-oxoguanine DNA glycosylase 1 (OGG1) in human lymphocytes is not dependent on genetic polymorphism Ser326/Cys326. Mutat Res 486, 207-16.
41. Dherin, C., J.P. Radicella, M. Dizdaroglu, and S. Boiteux. (1999). Excision of oxidatively damaged DNA bases by the human alpha-hOgg1 protein and the polymorphic alpha-hOgg1(Ser326Cys) protein which is frequently found in human populations. Nucleic Acids Res 27, 4001-7.
42. Hardie, L.J., J.A. Briggs, L.A. Davidson, J.M. Allan, R.F. King, G.I. Williams, and C.P. Wild. (2000). The effect of hOGG1 and glutathione peroxidase I genotypes and 3p chromosomal loss on 8-hydroxydeoxy-guanosine levels in lung cancer. Carcinogenesis 21, 167-72.
43. Park, Y.J., E.Y. Choi, J.Y. Choi, J.G. Park, H.J. You, and M.H. Chung. (2001). Genetic changes of hOGG1 and the activity of oh8Gua glycosylase in colon cancer. Eur J Cancer 37, 340-6.
44. Kondo, S., S. Toyokuni, T. Tanaka, H. Hiai, H. Onodera, H. Kasai, and M. Imamura. (2000). Overexpression of the hOGG1 gene and high 8-hydroxy-2′- deoxyguanosine (8-OHdG) lyase activity in human colorectal carcinoma: regulation mechanism of the 8-OHdG level in DNA. Clin Cancer Res 6, 1394-400.
45. Blons, H., J.P. Radicella, O. Laccourreye, D. Brasnu, P. Beaune, S. Boiteux, and P. Laurent-Puig. (1999). Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer. Mol Carcinog 26, 254-60.
46. Hu, Y.C. and S.A. Ahrendt. (2005). hOGG1 Ser326Cys polymorphism and G: C-to-T: A mutations: no evidence for a role in tobacco-related non small cell lung cancer. Int J Cancer 114, 387-93.
47. Tarng, D.C., T.J. Tsai, W.T. Chen, T.Y. Liu, and Y.H. Wei. (2001). Effect of human OGG1 1245C - >G gene polymorphism on 8-hydroxy-2′- deoxyguanosine levels of leukocyte DNA among patients undergoing chronic hemodialysis. J Am Soc Nephrol 12, 2338-47.
48. Chen, S.K., W.A. Hsieh, M.H. Tsai, C.C. Chen, A.I. Hong, Y.H. Wei, and W.P. Chang. (2003). Age-associated decrease of oxidative repair enzymes, human 8-oxoguanine DNA glycosylases (hOgg1), in human aging. J Radiat Res 44, 31-5.
49. Yamane, A., T. Kohno, K. Ito, N. Sunaga, K. Aoki, K. Yoshimura, H. Murakami, Y. Nojima, and J. Yokota. (2004). Differential ability of polymorphic OGG1 proteins to suppress mutagenesis induced by 8-hydroxyguanine in human cell in vivo. Carcinogenesis 25, 1689-94.
50. Xing, D.Y., W. Tan, N. Song, and D.X. Lin. (2001). Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 95, 140-3.
51. Sugimura, H., T. Kohno, K. Wakai, K. Nagura, K. Genka, H. Igarashi, B.J. Morris, S. Baba, Y. Ohno, C. Gao, Z. Li, J. Wang, T. Takezaki, K. Tajima, T. Varga, T. Sawaguchi, J.K. Lum, J.J. Martinson, S. Tsugane, T. Iwamasa, K. Shinmura, and J. Yokota. (1999). hOGG1 Ser326Cys polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 8, 669-74.
52. Wikman, H., A. Risch, F. Klimek, P. Schmezer, B. Spiegelhalder, H. Dienemann, K. Kayser, V. Schulz, P. Drings, and H. Bartsch (2000). hOGG1 polymorphism and loss of heterozygosity (LOH): significance for lung cancer susceptibility in a Caucasian population. Int J Cancer 88, 932-7.
53. Ito, H., N. Hamajima, T. Takezaki, K. Matsuo, K. Tajima, S. Hatooka, T. Mitsudomi, M. Suyama, S. Sato, and R. Ueda. (2002). A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. J Epidemiol 12, 258-65.
54. Le Marchand, L., T. Donlon, A. Lum-Jones, A. Seifried, and L.R. Wilkens. (2002). Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 11, 409-12.
55. Sunaga, N., T. Kohno, N. Yanagitani, H. Sugimura, H. Kunitoh, T. Tamura, Y. Takei, S. Tsuchiya, R. Saito, and J. Yokota. (2002). Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. Cancer Epidemiol Biomarkers Prev 11, 730-8.
56. Lan, Q., J.L. Mumford, M. Shen, D.M. Demarini, M.R. Bonner, X. He, M. Yeager, R. Welch, S. Chanock, L. Tian, R.S. Chapman, T. Zheng, P. Keohavong, N. Caporaso, and N. Rothman. (2004). Oxidative damage-related genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 25, 2177-81.
57. Park, J., L. Chen, M.S. Tockman, A. Elahi, and P. Lazarus. (2004). The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. Pharmacogenetics 14, 103-9.
58. Hung, R.J., P. Brennan, F. Canzian, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, L. Foretova, V. Janout, V. Bencko, A. Chabrier, S. Borel, J. Hall, and P. Boffetta. (2005). Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 97, 567-76.
59. Cho, E.Y., A. Hildesheim, C.J. Chen, M.M. Hsu, I.H. Chen, B.F. Mittl, P.H. Levine, M.Y. Liu, J.Y. Chen, L.A. Brinton, Y.J. Cheng, and C.S. Yang. (2003). Nasopharyngeal carcinoma and genetic polymorphisms of DNA repair enzymes XRCC1 and hOGG1. Cancer Epidemiol Biomarkers Prev 12, 1100-4.
60. Hao, B., H. Wang, K. Zhou, Y. Li, X. Chen, G. Zhou, Y. Zhu, X. Miao, W. Tan, Q. Wei, D. Lin, and F. He. (2004). Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 64, 4378-84.
61. Elahi, A., Z. Zheng, J. Park, K. Eyring, T. McCaffrey, and P. Lazarus. (2002). The human OGG1 DNA repair enzyme and its association with orolaryngeal cancer risk. Carcinogenesis 23, 1229-34.
62. Kim, J.I., Y.J. Park, K.H. Kim, B.J. Song, M.S. Lee, C.N. Kim, and S.H. Chang. (2003). hOGG1 Ser326Cys polymorphism modifies the significance of the environmental risk factor for colon cancer. World J Gastroenterol 9, 956-60.
63. Wang, Y., M.R. Spitz, Y. Zhu, Q. Dong, S. Shete, and X. Wu. (2003). From genotype to phenotype: correlating XRCC1 polymorphisms with mutagen sensitivity. DNA Rep 2, 901-8.
64. Matullo, G., S. Guarrera, S. Carturan, M. Peluso, C. Malaveille, L. Davico, A. Piazza, and P. Vineis. (2001). DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 92(4), 562-7.
65. Hu, J.J., T.R. Smith, M.S. Miller, H.W. Mohrenweiser, A. Golden, and L.D. Case. (2001). Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22, 917-22.
66. Hu, J.J., T.R. Smith, M.S. Miller, K. Lohman, and L.D. Case. (2002). Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen 39, 208-15.
67. Lunn, R.M., D.A. Bell, J.L. Mohler, and J.A. Taylor. (1999). Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 20, 1727-31.
68. Lunn, R.M., R.G. Langlois, L.L. Hsieh, C.L. Thompson, and D.A. Bell. (1999). XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59, 2557-61.
69. Matullo, G., D. Palli, M. Peluso, S. Guarrera, S. Carturan, E. Celentano, V. Krogh, A. Munnia, R. Tumino, S. Polidoro, A. Piazza, and P. Vineis. (2001). XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 22, 1437-45.
70. Fan, J., M. Otterlei, H.K. Wong, A.E. Tomkinson, and D.M. Wilson, 3rd. (2004). XRCC1 co-localizes and physically interacts with PCNA. Nucleic Acids Res 32, 2193-201.
71. Tuimala, J., G. Szekely, S. Gundy, A. Hirvonen, and H. Norppa. (2002). Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: role in mutagen sensitivity. Carcinogenesis 23, 1003-8.
72. Xi, T., I.M. Jones, and H.W. Mohrenweiser. (2004). Many amino acid substitution variants identified in DNA repair genes during human population screenings are predicted to impact protein function. Genomics 83, 970-9.
73. Hadi, M.Z., M.A. Coleman, K. Fidelis, H.W. Mohrenweiser, and D.M. Wilson, 3rd. (2000). Functional characterization of Ape1 variants identified in the human population. Nucleic Acids Res 28, 3871-9.
74. Dantzer, F., V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia, and G. de Murcia. (1999). Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81, 69-75.
75. Wieler, S., J.P. Gagne, H. Vaziri, G.G. Poirier, and S. Benchimol. (2003). Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 278, 18914-21.
76. Caldecott, K.W., C.K. McKeown, J.D. Tucker, S. Ljungquist, and L.H. Thompson. (1994). An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III. Mol Cell Biol. 14, 68-76.
77. Sancar, G.B., W. Siede, and A.A. van Zeeland. (1996). Repair and processing of DNA damage: a summary of recent progress. Mutat Res 362, 127-46.
78. Yu, M.W., S.Y. Yang, I.J. Pan, C.L. Lin, C.J. Liu, Y.F. Liaw, S.M. Lin, P.J. Chen, S.D. Lee, and C.J. Chen. (2003). Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst 95, 1485-8.
79. Spitz, M.R., X. Wu, Y. Wang, L.E. Wang, S. Shete, C.I. Amos, Z. Guo, L. Lei, H. Mohrenweiser, and Q. Wei. (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61, 1354-7.
80. Baccarelli, A., D. Calista, P. Minghetti, B. Marinelli, B. Albetti, T. Tseng, M. Hedayati, L. Grossman, G. Landi, J.P. Struewing, and M.T. Landi. (2004). XPD gene polymorphism and host characteristics in the association with cutaneous malignant melanoma risk. Br J Cancer 90, 497-502.
81. Benhamou, S., and A. Sarasin. (2005). ERCC2 /XPD gene polymorphisms and lung cancer: a HuGE review. Am J Epidemiol 161, 1-14.
82. Hou, S.M., S. Falt, S. Angelini, K. Yang, F. Nyberg, B. Lambert, and K. Hemminki. (2002). The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 23, 599-603.
83. Lunn, R.M., K.J. Helzlsouer, R. Parshad, D.M. Umbach, E.L. Harris, K.K. Sanford, and D.A. Bell. (2000). XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21, 551-5.
84. Duell, E.J., J.K. Wiencke, T.J. Cheng, A. Varkonyi, Z.F. Zuo, T.D. Ashok, E.J. Mark, J.C. Wain, D.C. Christiani, and K.T. Kelsey. (2000). Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 21, 965-71.
85. Kiyohara, C., and K. Yoshimasu. (2007). Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci 4, 59-71.
86. Huang, W.Y., S.I. Berndt, D. Kang, N. Chatterjee, S.J. Chanock, M. Yeager, R. Welch, R.S. Bresalier, J.L. Weissfeld, and R.B. Hayes. (2006). Nucleotide excision repair gene polymorphisms and risk of advanced colorectal adenoma: XPC polymorphisms modify smoking-related risk. Cancer Epidemiol Biomarkers Prev 15, 306-11.
87. Mohrenweiser, H.W., D.M. Wilson, 3rd, and I.M. Jones. (2003). Challenges and complexities in estimating both the functional impact and the disease risk associated with the extensive genetic variation in human DNA repair genes. Mutat Res 526, 93-125.
88. Araujo, F.D., A.J. Pierce, J.M. Stark, and M. Jasin. (2002). Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks. Oncogene 21, 4176-80.
89. Nonoyama, S., and H.D. Ochs. (1996). Immune deficiency in SCID mice. Int Rev Immunol 13, 289-300.
90. Nicolas, N., D. Moshous, M. Cavazzana-Calvo, D. Papadopoulo, R. de Chasseval, F. Le Deist, A. Fischer, and J.P. de Villarta. (1998). A human severe combined immunodeficiency (SCID) condition with increased sensitivity to ionizing radiations and impaired V(D)J rearrangements defines a new DNA recombination/repair deficiency. J Exp Med 188, 627-34.
91. Dip, R. and H. Naegeli. (2005). More than just strand breaks: the recognition of structural DNA discontinuities by DNA-dependent protein kinase catalytic subunit. FASEB J 19, 704-15.
92. Sipley, J.D., J.C. Menninger, K.O. Hartley, D.C. Ward, S.P. Jackson, and C.W. Anderson. (1995). Gene for the catalytic subunit of the human DNA-activated protein kinase maps to the site of the XRCC7 gene on chromosome 8. Proc Natl Acad Sci U S A 92, 7515-9.
93. Zhang, Y., J. Zhou, and C.U. Lim. (2006). The role of NBS1 in DNA double strand break repair, telomere stability, and cell cycle checkpoint control. Cell Res 16, 45-54.
94. Medina, P.P., S.A. Ahrendt, M. Pollan, P. Fernandez, D. Sidransky, and M. Sanchez-Cespedes. (2003). Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. Cancer Epidemiol Biomarkers Prev 12, 699-704.
95. Margison, G.P., A.C. Povey, B. Kaina, and M.F. Santibanez Koref. (2003). Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24, 625-35.
96. Inoue, R., M. Abe, Y. Nakabeppu, M. Sekiguchi, T. Mori, and T. Suzuki. (2000). Characterization of human polymorphic DNA repair methyltransferase. Pharmacogenetics 10, 59-66.
97. Margison, G.P., J. Heighway, S. Pearson, G. McGown, M.R. Thorncroft, A.J. Watson, K.L. Harrison, S.J. Lewis, K. Rohde, P.V. Barber, P. O'Donnell, A.C. Povey, and M.F. Santibanez-Koref. 92005). Quantitative trait locus analysis reveals two intragenic sites that influence O6-alkylguanine-DNA alkyltransferase activity in peripheral blood mononuclear cells. Carcinogenesis 26, 1473-80.
98. Matsuoka, S., G. Rotman, A. Ogawa, Y. Shiloh, K. Tamai, and S.J. Elledge. (2000). Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci USA 97, 10389-94.
99. Kim, J.H., H. Kim, K.Y. Lee, K.H. Choe, J.S. Ryu, H.I. Yoon, S.W. Sung, K.Y. Yoo, and Y.C. Hong. (2006). Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. Hum Mol Genet 15, 1181-6.
100. Koren, M., G. Kimmel, E. Ben-Asher, I. Gal, M.Z. Papa, J.S. Beckmann, D. Lancet, R. Shamir, and E. Friedman. (2006). ATM haplotypes and breast cancer risk in Jewish highrisk women. Br J Cancer 94, 1537-43.
101. Lee, K.M., J.Y. Choi, S.K. Park, H.W. Chung, B. Ahn, K.Y. Yoo, W. Han, D.Y. Noh, S.H. Ahn, H. Kim, Q. Wei, and D. Kang. (2005). Genetic polymorphisms of ataxia telangiectasia mutated and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14, 821-5.
102. Audebert, M., J.P. Radicella, and M. Dizdaroglu. (2000). Effect of single mutations in the OGG1 gene found in human tumors on the substrate specificity of the Ogg1 protein. Nucleic Acids Res 28, 2672-8.
103. Chen, C., N.S. Weiss, F.Z. Stanczyk, S.K. Lewis, D. DiTommaso, R. Etzioni, M.J. Barnett, and G.E. Goodman. (2003). Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol Biomarkers Prev 12, 1410-6.
104. Peng, T., H.M. Shen, Z.M. Liu, L.N. Yan, M.H. Peng, L.Q. Li, R.X. Liang, Z.L. Wei, B. Halliwell, and C.N. Ong. (2003). Oxidative DNA damage in peripheral leukocytes and its association with expression and polymorphisms of hOGG1: a study of adolescents in a high risk region for hepatocellular carcinoma in China. World J Gastroenterol 9, 2186-93.
105. Khan, S.G., E.J. Metter, R.E. Tarone, V.A. Bohr, L. Grossman, M. Hedayati, S.J. Bale, S. Emmert, and K.H. Kraemer. (2000). A new xeroderma pigmentosum group C poly(AT) insertion/deletion polymorphism. Carcinogenesis 21, 1821-5.
106. Wang, C.Y., R.F. Jones, M. Debiec-Rychter, G. Soos, and G.P. Haas. (2002). Correlation of the genotypes for N-acetyltransferases 1 and 2 with double bladder and prostate cancers in a case-comparison study. Anticancer Res 22, 3529-35.